CD4 and neoplasm: Considering that both tumor-blood overlapping clones and MHC class I gene expression increased in the IT1208 responders (Cases 3 and 10), the increase of tumor-blood overlapping CD8+ TCR clones and MHC class I gene expression may reflect the mode of action of CD4 depletion [17] and may be a response marker to IT1208 treatment.